Amarin Corp Plcuk (AMRN) Common Equity (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Common Equity of $449.4 million for Q1 2026, down 5.12% year-over-year from $473.7 million in Q1 2025, and down 2.15% quarter-over-quarter from $459.3 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Common Equity (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Common Equity data on file, last reported at $449.4 million in Q1 2026.
- Common Equity for Q1 2026 came in at $449.4 million, down 5.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $449.4 million (down 5.12% YoY), and the FY2025 annual result was $459.3 million, down 5.53% from the prior year.
- Common Equity slipped to $449.4 million in Q1 2026 per AMRN's latest filing, from $459.3 million in the prior quarter.
- Over five years, Common Equity peaked at $641.1 million in Q1 2022 and troughed at $449.4 million in Q1 2026.
- A 5-year average of $534.4 million and a median of $551.9 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity rose 1.02% in 2022, then retreated 15.76% in 2025.
- A 5-year view of Common Equity shows it stood at $595.3 million in 2022, then declined by 7.26% to $552.1 million in 2023, then retreated by 11.94% to $486.2 million in 2024, then fell by 5.53% to $459.3 million in 2025, then fell by 2.15% to $449.4 million in 2026.
- Business Quant data shows AMRN's Common Equity at $449.4 million in Q1 2026, $459.3 million in Q4 2025, and $458.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 23.49 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 31.20 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 81.19 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -6.61 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 45.93 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 9.19 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 23.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 90.40 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 20.10 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 449.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 449.41 Mn |
| Dec 31, 2025 | 459.28 Mn |
| Sep 30, 2025 | 458.89 Mn |
| Jun 30, 2025 | 464.92 Mn |
| Mar 31, 2025 | 473.69 Mn |
| Dec 31, 2024 | 486.18 Mn |
| Sep 30, 2024 | 531.38 Mn |
| Jun 30, 2024 | 551.88 Mn |
| Mar 31, 2024 | 545.94 Mn |
| Dec 31, 2023 | 552.10 Mn |
| Sep 30, 2023 | 553.15 Mn |
| Jun 30, 2023 | 569.13 Mn |
| Mar 31, 2023 | 584.79 Mn |
| Dec 31, 2022 | 595.33 Mn |
| Sep 30, 2022 | 587.83 Mn |
| Jun 30, 2022 | 580.04 Mn |
| Mar 31, 2022 | 641.11 Mn |
| Dec 31, 2021 | 667.10 Mn |
| Sep 30, 2021 | 642.50 Mn |
| Jun 30, 2021 | 645.32 Mn |